Logo image of HALO

HALOZYME THERAPEUTICS INC (HALO) Stock Fundamental Analysis

NASDAQ:HALO - US40637H1095 - Common Stock

76.19 USD
+0.39 (+0.51%)
Last: 9/11/2025, 11:03:42 AM
Fundamental Rating

8

Overall HALO gets a fundamental rating of 8 out of 10. We evaluated HALO against 541 industry peers in the Biotechnology industry. HALO gets an excellent profitability rating and is at the same time showing great financial health properties. HALO is growing strongly while it also seems undervalued. This is an interesting combination With these ratings, HALO could be worth investigating further for value and growth and quality investing!.


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

In the past year HALO was profitable.
HALO had a positive operating cash flow in the past year.
In the past 5 years HALO has always been profitable.
In the past 5 years HALO always reported a positive cash flow from operatings.
HALO Yearly Net Income VS EBIT VS OCF VS FCFHALO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

1.2 Ratios

HALO's Return On Assets of 27.13% is amongst the best of the industry. HALO outperforms 97.78% of its industry peers.
HALO's Return On Equity of 167.48% is amongst the best of the industry. HALO outperforms 99.63% of its industry peers.
The Return On Invested Capital of HALO (28.55%) is better than 98.71% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for HALO is in line with the industry average of 15.95%.
The last Return On Invested Capital (28.55%) for HALO is above the 3 year average (17.81%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 27.13%
ROE 167.48%
ROIC 28.55%
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
HALO Yearly ROA, ROE, ROICHALO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 200 300

1.3 Margins

Looking at the Profit Margin, with a value of 47.28%, HALO belongs to the top of the industry, outperforming 98.89% of the companies in the same industry.
HALO's Profit Margin has declined in the last couple of years.
HALO has a better Operating Margin (57.92%) than 99.82% of its industry peers.
In the last couple of years the Operating Margin of HALO has declined.
With an excellent Gross Margin value of 84.20%, HALO belongs to the best of the industry, outperforming 87.25% of the companies in the same industry.
In the last couple of years the Gross Margin of HALO has grown nicely.
Industry RankSector Rank
OM 57.92%
PM (TTM) 47.28%
GM 84.2%
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
HALO Yearly Profit, Operating, Gross MarginsHALO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

8

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), HALO is creating value.
Compared to 1 year ago, HALO has less shares outstanding
HALO has less shares outstanding than it did 5 years ago.
HALO has a better debt/assets ratio than last year.
HALO Yearly Shares OutstandingHALO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
HALO Yearly Total Debt VS Total AssetsHALO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

An Altman-Z score of 5.59 indicates that HALO is not in any danger for bankruptcy at the moment.
HALO has a Altman-Z score of 5.59. This is in the better half of the industry: HALO outperforms 77.08% of its industry peers.
HALO has a debt to FCF ratio of 2.79. This is a good value and a sign of high solvency as HALO would need 2.79 years to pay back of all of its debts.
HALO has a Debt to FCF ratio of 2.79. This is amongst the best in the industry. HALO outperforms 94.08% of its industry peers.
A Debt/Equity ratio of 4.54 is on the high side and indicates that HALO has dependencies on debt financing.
The Debt to Equity ratio of HALO (4.54) is worse than 82.26% of its industry peers.
Industry RankSector Rank
Debt/Equity 4.54
Debt/FCF 2.79
Altman-Z 5.59
ROIC/WACC3.19
WACC8.96%
HALO Yearly LT Debt VS Equity VS FCFHALO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 8.36 indicates that HALO has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 8.36, HALO is in the better half of the industry, outperforming 75.05% of the companies in the same industry.
HALO has a Quick Ratio of 7.01. This indicates that HALO is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of HALO (7.01) is better than 69.69% of its industry peers.
Industry RankSector Rank
Current Ratio 8.36
Quick Ratio 7.01
HALO Yearly Current Assets VS Current LiabilitesHALO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 58.41% over the past year.
HALO shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 30.12% yearly.
HALO shows a strong growth in Revenue. In the last year, the Revenue has grown by 34.97%.
Measured over the past years, HALO shows a very strong growth in Revenue. The Revenue has been growing by 38.95% on average per year.
EPS 1Y (TTM)58.41%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%69.23%
Revenue 1Y (TTM)34.97%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%40.79%

3.2 Future

HALO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.63% yearly.
HALO is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.63% yearly.
EPS Next Y47.96%
EPS Next 2Y38.15%
EPS Next 3Y32.51%
EPS Next 5Y17.63%
Revenue Next Year31.57%
Revenue Next 2Y27.35%
Revenue Next 3Y23.97%
Revenue Next 5Y12.63%

3.3 Evolution

Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
HALO Yearly Revenue VS EstimatesHALO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B
HALO Yearly EPS VS EstimatesHALO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 4 6 8 10

More info and screens

9

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 14.71, which indicates a correct valuation of HALO.
Compared to the rest of the industry, the Price/Earnings ratio of HALO indicates a rather cheap valuation: HALO is cheaper than 95.56% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.03, HALO is valued a bit cheaper.
Based on the Price/Forward Earnings ratio of 9.44, the valuation of HALO can be described as reasonable.
HALO's Price/Forward Earnings ratio is rather cheap when compared to the industry. HALO is cheaper than 97.23% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.54, HALO is valued rather cheaply.
Industry RankSector Rank
PE 14.71
Fwd PE 9.44
HALO Price Earnings VS Forward Price EarningsHALO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

95.19% of the companies in the same industry are more expensive than HALO, based on the Enterprise Value to EBITDA ratio.
95.93% of the companies in the same industry are more expensive than HALO, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 16.48
EV/EBITDA 12.22
HALO Per share dataHALO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8 10

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
HALO has an outstanding profitability rating, which may justify a higher PE ratio.
HALO's earnings are expected to grow with 32.51% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.31
PEG (5Y)N/A
EPS Next 2Y38.15%
EPS Next 3Y32.51%

More info and screens

0

5. Dividend

5.1 Amount

HALO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HALOZYME THERAPEUTICS INC

NASDAQ:HALO (9/11/2025, 11:03:42 AM)

76.19

+0.39 (+0.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-05 2025-08-05/amc
Earnings (Next)10-29 2025-10-29/amc
Inst Owners100.38%
Inst Owner Change5.29%
Ins Owners0.82%
Ins Owner Change0.18%
Market Cap8.91B
Analysts75
Price Target72.93 (-4.28%)
Short Float %9.15%
Short Ratio4.58
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.03%
Min EPS beat(2)14.79%
Max EPS beat(2)19.26%
EPS beat(4)4
Avg EPS beat(4)16.87%
Min EPS beat(4)6.64%
Max EPS beat(4)26.79%
EPS beat(8)7
Avg EPS beat(8)12.25%
EPS beat(12)10
Avg EPS beat(12)12.69%
EPS beat(16)13
Avg EPS beat(16)10.59%
Revenue beat(2)2
Avg Revenue beat(2)12.25%
Min Revenue beat(2)11.69%
Max Revenue beat(2)12.81%
Revenue beat(4)4
Avg Revenue beat(4)9.78%
Min Revenue beat(4)1.36%
Max Revenue beat(4)13.28%
Revenue beat(8)5
Avg Revenue beat(8)5.19%
Revenue beat(12)7
Avg Revenue beat(12)3.36%
Revenue beat(16)9
Avg Revenue beat(16)2.8%
PT rev (1m)7.32%
PT rev (3m)1.32%
EPS NQ rev (1m)10.4%
EPS NQ rev (3m)18.67%
EPS NY rev (1m)11.56%
EPS NY rev (3m)17.41%
Revenue NQ rev (1m)2.68%
Revenue NQ rev (3m)2.34%
Revenue NY rev (1m)5.73%
Revenue NY rev (3m)5.4%
Valuation
Industry RankSector Rank
PE 14.71
Fwd PE 9.44
P/S 7.56
P/FCF 16.48
P/OCF 16.27
P/B 26.78
P/tB N/A
EV/EBITDA 12.22
EPS(TTM)5.18
EY6.8%
EPS(NY)8.07
Fwd EY10.6%
FCF(TTM)4.62
FCFY6.07%
OCF(TTM)4.68
OCFY6.15%
SpS10.08
BVpS2.84
TBVpS-3.85
PEG (NY)0.31
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 27.13%
ROE 167.48%
ROCE 35.56%
ROIC 28.55%
ROICexc 39.96%
ROICexgc 93.15%
OM 57.92%
PM (TTM) 47.28%
GM 84.2%
FCFM 45.87%
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
ROICexc(3y)23.94%
ROICexc(5y)N/A
ROICexgc(3y)71.73%
ROICexgc(5y)N/A
ROCE(3y)22.19%
ROCE(5y)37.11%
ROICexcg growth 3Y-1.13%
ROICexcg growth 5YN/A
ROICexc growth 3Y-28.16%
ROICexc growth 5YN/A
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
F-Score8
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 4.54
Debt/FCF 2.79
Debt/EBITDA 1.97
Cap/Depr 8.67%
Cap/Sales 0.6%
Interest Coverage 250
Cash Conversion 71.66%
Profit Quality 97.02%
Current Ratio 8.36
Quick Ratio 7.01
Altman-Z 5.59
F-Score8
WACC8.96%
ROIC/WACC3.19
Cap/Depr(3y)13.62%
Cap/Depr(5y)33.32%
Cap/Sales(3y)1.21%
Cap/Sales(5y)0.98%
Profit Quality(3y)118.15%
Profit Quality(5y)93.9%
High Growth Momentum
Growth
EPS 1Y (TTM)58.41%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%69.23%
EPS Next Y47.96%
EPS Next 2Y38.15%
EPS Next 3Y32.51%
EPS Next 5Y17.63%
Revenue 1Y (TTM)34.97%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%40.79%
Revenue Next Year31.57%
Revenue Next 2Y27.35%
Revenue Next 3Y23.97%
Revenue Next 5Y12.63%
EBIT growth 1Y68.72%
EBIT growth 3Y25.97%
EBIT growth 5YN/A
EBIT Next Year48.84%
EBIT Next 3Y31.32%
EBIT Next 5Y15.57%
FCF growth 1Y84.66%
FCF growth 3Y16.28%
FCF growth 5YN/A
OCF growth 1Y79.07%
OCF growth 3Y16.96%
OCF growth 5YN/A